Effect of combined oral contraceptive use on serum 25-hydroxy vitamin D levels and ultrasound parameters in patients with polycystic ovary syndrome

Abstract

Purpose: To investigate if there is an effect of combined oral contraceptive (COC) use on serum 25-hydroxy vitamin D [25(OH)D] levels in patients with polycystic ovary syndrome (PCOS).

Methods: PCOS was defined by the 2003 Rotterdam criteria. All patients with PCOS were treated with a COC containing 0.035 mg ethinylestradiol and 2 mg cyproterone acetate for 6 months. Serum 25(OH)D levels, HOMA–IR, ovarian volume and antral follicule count were measured before and after the treatment.

Results: The median 25(OH)D levels were 9.40 (range 4.40–24.50) μg/l and 7.00 (5.00–13.50) μg/l before and after COC use, respectively. Serum 25(OH)D levels decreased after the treatment; however, the difference was not statistically significant (p = 0.055).

Conclusion: This study seems to be the first prospective trial revealing the effect of COC use on serum 25(OH)D levels in women with PCOS. Although the decrease in serum 25(OH)D levels in patients with PCOS with the use of COC alone, did not reach to statistically significance level after 6 months treatment with COC.

Chinese abstract

目的：探讨复方口服避孕药(COC)是否对多囊卵巢综合征(PCOS)患者血清25-羟基维生素D（25-OHD）水平有影响。

方法：PCOS诊断基于2003鹿特丹诊断标准。所有PCOS患者服用含有0.035mg炔雌醇和2mg醋酸环丙孕酮的复方口服避孕药治疗六个月，并于治疗前后分别检查血清25-OHD水平，HOMA–IR公式计算的IR值，卵巢体积和窦卵泡数量。

结果：血清25-OHD水平在治疗前后分别是9.40（范围4.40-24.50）mg/l和7.00（5.00-13.50）mg/l，差别无统计学意义(p=0.055)。

结论：研究首次以前瞻性研究方法揭示COC对患PCOS女性血清25-OHD的影响，PCOS患者单独服用COC治疗6个月血清25-OHD下降水平无统计学意义。

• Contraception
• hormonal
• insulin resistance
• polycystic ovary syndrome

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.